- Full-year revenue up 15.5 per cent to £56mn
- Earnings upgrades for 2023 and 2024
- £80mn contracted order book
- 90 per cent of 2024 sales budget contracted
- Net cash rises 30 per cent to £37mn
Aim-traded hVIVO (HVO:29.35p), a fast-growing specialist contract research organisation (CRO), has upgraded earnings guidance yet again.
hVIVO provides early clinical development services for a broad and loyal client base of biopharma companies. It is the only CRO focused on challenge studies, providing expertise and capabilities in challenge agent manufacturing. It has a portfolio of human challenge models to test a range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services.